Author [ Title] Type Year
Filters: Author is Zweegman, Sonja [Clear All Filters]
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis. Cell Rep. 2018;25(11):3021-3035.e5.
Lenalidomide plus melphalan and prednisone, followed by lenalidomide maintenance versus thalidomide plus melphalan and prednisone, followed by thalidomide maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial. Blood. 2016.
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. PLoS One. 2014;9(9):e107587.
Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2014.
Reduced relapse rate in upfront tandem autologous/reduced intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression free and not of overall survival. Haematologica. 2015.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.